Oversight of ‘Right to Try’ Stem Cell Market Raises Concerns, Bioethicists Say

November 5, 2019

(S & P Global) – Already troubled by the murky oversight of the rapidly expanding U.S. direct-to-consumer marketplace of unapproved stem cell therapies, bioethicists are now raising concerns about a new pathway that at least one company is taking to sell those products — the Right to Try Act. The law, adopted in May 2018, allows critically ill patients to sidestep the U.S. Food and Drug Administration in seeking access to experimental therapies. The growing unapproved stem cell market combined with the congressionally mandated laissez-faire approach for Right to Try, or RTT, could expose vulnerable patients to harm, bioethicists told S&P Global Market Intelligence.

Recommended Reading